Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
442.00    -4.00 (-0.90%)
Bid:
440.00
Ask:
441.50
Spread: 1.50 (0.341%)
Market Cap: £217.38m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Trading Update

10 Jul 2015 07:00

RNS Number : 6817S
Zotefoams PLC
10 July 2015
 



Zotefoams plc

("Zotefoams" or "the Company")

 

Trading Update

 

 

10 July 2015 - Zotefoams, a world leader in cellular material technology, today provides a trading update for the six months ended 30 June 2015.

 

For the first six months of 2015 Zotefoams will deliver sales1 growth of approximately 8%, which is approximately 10% on a constant currency basis. Zotefoams expects revenue from MuCell Extrusion LLC, the Company's technology licensing business, to grow by around 40% and High-Performance Products ("HPP") sales growth to exceed 20%, building on the very strong HPP performance in 2014. The Company's Polyolefin foams sales volumes have increased by 6% and this is expected to deliver an increase in revenue of approximately 5%, equivalent to around 8% in constant currency. All three business units have strong forward order books.

 

The price of LDPE (Low Density Polyethylene), the Company's major raw material, was at a similar average euro price to the first half of 2014, although prices have risen sharply in recent months. The weaker euro has benefitted raw material purchases, which are significantly euro based, and US dollar sales have benefitted from the stronger dollar. However this has been more than offset by the impact of the euro on both Zotefoams' European sales and, in particular, the unhedged translational impact on the Company's balance sheet.

 

In Walton, Kentucky, USA, the major investment to increase global manufacturing capacity in support of future growth is proceeding to schedule.

 

Whilst being mindful of the potential impact of economic conditions the Company continues to expect 2015 to be another year of progress and remains confident about the long-term prospects for the business.

 

Zotefoams expects to announce its interim results for the six months ended 30 June 2015 on Tuesday 4 August 2015.

 

 

Enquiries:

Zotefoams plc

David Stirling, Group CEO

0208-664-1600

Clifford Hurst, Finance Director

FTI Consulting

0203-727-1000

Victoria Foster Mitchell/Simon Conway

 

 

Notes

 

1 Sales consolidates all external sales made by the joint-ventures as well as those made by Zotefoams plc and its subsidiaries.

2 Foreign exchange rates were:

 

H1:2015 average

H1:2014 average

30 Jun 2015

31 Dec 2014

Euro

1.378

1.223

1.412

1.289

USD

1.530

1.673

1.574

1.559

 

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular material technology. Using a unique manufacturing process with environmentally friendly nitrogen expansion, Zotefoams produces lightweight foams in Croydon, UK and Kentucky, USA for diverse markets worldwide through its global sales force. Zotefoams also owns and licenses patented MuCell® microcellular foam technology from a base in Massachusetts, USA to customers worldwide and sells T-Tubes® advanced insulation systems made from its patented ZOTEK® fluoropolymer foams.

 

www.zotefoams.com

 

ZOTEK® is a registered trademark of Zotefoams plc. MuCell® is a registered trademark of Trexel Inc. T-Tubes® is a registered trademark of UFP Technologies Inc.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFMGGNZLMGKZZ
Date   Source Headline
11th Aug 20094:19 pmRNSHolding(s) in Company
10th Aug 200912:45 pmRNSHolding(s) in Company
4th Aug 20097:00 amRNSHalf Yearly Report
20th Jul 20091:42 pmRNSHolding(s) in Company
3rd Jul 20097:00 amRNSTrading Statement
17th Jun 20095:33 pmRNSHolding(s) in Company
5th Jun 200912:23 pmRNSDirector/PDMR Shareholding
19th May 200910:30 amRNSAnnual Information Update
12th May 200910:30 amRNSVoting Rights and Capital
7th May 20097:00 amRNSAGM Statement
7th Apr 200910:51 amRNSNotice of AGM
26th Mar 20097:00 amRNSAdditional Listing
18th Mar 20091:50 pmRNSDirector/PDMR Shareholding
16th Mar 20095:19 pmRNSDirector/PDMR Shareholding
10th Mar 20097:00 amRNSFinal Results
22nd Jan 200911:36 amRNSHolding(s) in Company
5th Jan 20091:19 pmRNSVoting Rights and Capital
19th Dec 20087:00 amRNSTrading Statement
12th Dec 200811:04 amRNSDirector/PDMR Shareholding
11th Dec 20082:20 pmRNSHolding(s) in Company
3rd Nov 20087:00 amRNSInterim Management Statement
30th Oct 20082:25 pmRNSAdditional Listing
14th Aug 20087:00 amRNSDirector/PDMR Shareholding
5th Aug 20087:00 amRNSInterim Results
9th Jul 20089:11 amRNSAcquires Stake
1st Jul 20087:00 amRNSTrading Update
5th Jun 20089:37 amRNSVoting rights and capital
23rd May 20085:38 pmRNSAnnual Information Update
8th May 20087:01 amRNSAGM Statement
14th Apr 20087:00 amRNSBlocklisting Interim Review
8th Apr 20086:07 pmRNSAdditional Listing
8th Apr 20088:18 amRNSNotice of AGM
25th Mar 20082:46 pmRNSDirector/PDMR Shareholding
4th Mar 20087:01 amRNSFinal Results
3rd Mar 20087:00 amRNSCustomer Achievement
1st Feb 20081:46 pmRNSTotal Voting Rights
21st Dec 20072:48 pmRNSDirectors' Shareholdings
26th Nov 200710:04 amRNSAdditional Listing
12th Nov 20077:01 amRNSDirector/PDMR Shareholding
7th Nov 20078:45 amRNSDirectors' Shareholdings
30th Oct 20072:55 pmRNSHolding in Company
19th Oct 20077:01 amRNSProduct Achievement
17th Oct 20079:32 amRNSBlocklisting Interim Review
5th Sep 200712:29 pmRNSHolding(s) in Company
28th Aug 20077:02 amRNSMarketing Alliance
7th Aug 20077:00 amRNSInterim Results
30th Jul 20074:45 pmRNSVoting rights & capital
12th Jul 20074:02 pmRNSDirectorate Change
29th Jun 200711:04 amRNSTrading Update
28th Jun 20072:23 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.